Status:
COMPLETED
Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-60 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the effects on cardiac repolarisation of supratherapeutic doses of AZD3480 compared to placebo in healthy male volunteers, subgrouped as extensive metabolisers...
Eligibility Criteria
Inclusion
- Participation in a previous study for genotyping for identification to be extensive or poor metaboliser (CYP2D6 enzyme)
- Physically and mentally healthy male volunteers
Exclusion
- History of clinically significant diseases or illness.
- Participation in another study the last 3 months
- Prescribed or non-prescribed medications from 3 weeks prior to first treatment day until follow-up except for paracetamol (max 1.5 g per day.)
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00686179
Start Date
January 1 2008
End Date
August 1 2008
Last Update
September 25 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.